- Home
- DVAX vs IRS Comparison
DVAX vs IRS Comparison
Compare DVAX & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- IRS
- Stock Information
- Founded
- DVAX 1996
- IRS 1943
- Country
- DVAX United States
- IRS Argentina
- Employees
- DVAX N/A
- IRS N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- IRS Homebuilding
- Sector
- DVAX Health Care
- IRS Real Estate
- Exchange
- DVAX Nasdaq
- IRS Nasdaq
- Market Cap
- DVAX 1.2B
- IRS 959.8M
- IPO Year
- DVAX 2004
- IRS 1994
- Fundamental
- Price
- DVAX $10.15
- IRS $11.36
- Analyst Decision
- DVAX Buy
- IRS
- Analyst Count
- DVAX 4
- IRS 0
- Target Price
- DVAX $26.50
- IRS N/A
- AVG Volume (30 Days)
- DVAX 1.7M
- IRS 301.2K
- Earning Date
- DVAX 11-06-2025
- IRS 11-05-2025
- Dividend Yield
- DVAX N/A
- IRS 8.73%
- EPS Growth
- DVAX N/A
- IRS N/A
- EPS
- DVAX N/A
- IRS 0.20
- Revenue
- DVAX $316,268,000.00
- IRS $416,589,564.00
- Revenue This Year
- DVAX $23.23
- IRS N/A
- Revenue Next Year
- DVAX $16.57
- IRS N/A
- P/E Ratio
- DVAX N/A
- IRS $5.67
- Revenue Growth
- DVAX 26.66
- IRS N/A
- 52 Week Low
- DVAX $9.20
- IRS $10.61
- 52 Week High
- DVAX $14.63
- IRS $17.67
- Technical
- Relative Strength Index (RSI)
- DVAX 52.11
- IRS 35.10
- Support Level
- DVAX $9.95
- IRS $11.25
- Resistance Level
- DVAX $10.35
- IRS $11.91
- Average True Range (ATR)
- DVAX 0.29
- IRS 0.63
- MACD
- DVAX 0.08
- IRS -0.03
- Stochastic Oscillator
- DVAX 75.00
- IRS 5.41
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.